Current Pharmaceutical Design
Title:Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
Volume: 19 Issue: 5
Author(s): E. Giovannetti and G.J. Peters
Affiliation:
Export Options
About this article
Cite this article as:
Giovannetti E. and Peters G.J., Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer), Current Pharmaceutical Design 2013; 19 (5) . https://dx.doi.org/10.2174/1381612811306050807
DOI https://dx.doi.org/10.2174/1381612811306050807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Importance of Pharmacist in Oxaliplatin Hepatotoxicity Associated with Inadequate Nutritional Diet: Case Report
Current Nutrition & Food Science A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry VEGFA and PlGF Protein Signature of Primary Stage IV Rectal Cancer Pre and Post Neoadjuvant Radiotherapy, Bevacizumab, and Chemotherapy
Current Angiogenesis (Discontinued) Regulation of MicroRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inhibition of Topoisomerase I by Anti-Cancer Drug Altered the Endometrial Cyclicity and Receptivity
Current Molecular Medicine The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study
Current Topics in Medicinal Chemistry Pharmacokinetics of 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), a Dual Acting Mutually Masking Prodrug, and Its Metabolites in Tumor Bearing Mice
Current Drug Delivery Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design